<DOC>
	<DOC>NCT01908894</DOC>
	<brief_summary>The primary objective is to assess the speed of absorption of BIOD-123 and BIOD-125 and compare them to Humalog.</brief_summary>
	<brief_title>Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration</brief_title>
	<detailed_description>The primary objective is to assess the speed of absorption of BIOD-123 and BIOD-125 and compare them to Humalog. The secondary objectives are to assess other pharmacokinetic characteristics of BIOD-123 and BIOD-125 and compare those to Humalog®, to assess pharmacodynamic characteristics of BIOD-123 and BIOD-125 and compare those to Humalog®, and to evaluate the safety and tolerability of BIOD-123 and BIOD-125 compared to Humalog®</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>1. Age: ≥18 ≤70 years 2. BMI: ≥18 ≤30 kg/m2 3. Diagnosed with type 1 diabetes mellitus for at least 1 year 4. Insulin antibody ≤10 μU/mL at screening 1. Type 2 diabetes mellitus 2. History of &gt;2 severe hypoglycemic events within the 3 months prior to screening 3. Serum Cpeptide &gt;1.0 ng/mL 4. Hemoglobin A1c (HbA1c) &gt;10.0% 5. Females who were breast feeding, pregnant, or intending to become pregnant during the study 6. A sexually active person who was not using adequate contraceptive methods 7. Positive serology for human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C 8. Abnormal ECG, safety lab, or physical examination results that were deemed clinically significant by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>